Michaela Jeong

Michaela Jeong

Auto-generated profile, based on publicly available information

Michaela Jeong

College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
MKM. Kim
M. Kim
MJM. Jeong
M. Jeong
SHS. Hur
S. Hur
YCY. Cho
Y. Cho
JPJiyoung Park
Jiyoung Park
HLHyukjin Lee
Hyukjin Lee
Engineered ionizable lipid nanoparticles (LNPs) were developed for the LSEC-specific delivery of RNA therapeutics.

21 January 2022 in Science Advances
Verified
Journal Article
Open access
JHJeongpil Han
Jeongpil Han
MKMinJeong Kim
MinJeong Kim
BCBeom Seok Choi
Beom Seok Choi
JLJeong Hyeon Lee
Jeong Hyeon Lee
GLGeon Seong Lee
Geon Seong Lee
SYSu Cheong Yeom
Su Cheong Yeom
Hemophilia is a hereditary disease that remains incurable. Although innovative treatments such as gene therapy or bispecific antibody therapy have been introduced, substantial unmet needs still exist with respect to achieving long-lasting therapeutic effects and treatment options for inhibitor patients. Antithrombin (AT), an endogenous negative regulator of thrombin generation, is a potent genome editing target for sustainable treatment of patients with hemophilia A and B. In this study, we developed and optimized lipid nanoparticles (LNPs) to deliver Cas9 mRNA along with single guide RNA that targeted AT in the mouse liver. The LNP-mediated CRISPR-Cas9 delivery resulted in the inhibition of AT that led to improvement in thrombin generation. Bleeding-associated phenotypes were recovered in both hemophilia A and B mice. No active off-targets, liver-induced toxicity, and substantial anti-Cas9 immune responses were detected, indicating that the LNP-mediated CRISPR-Cas9 delivery was a safe and efficient approach for hemophilia therapy.

1 January 2024 in Biomaterials Research
Verified
Journal Article
Open access
YLYeji Lee
Yeji Lee
MJMichaela Jeong
Michaela Jeong
GLGyeongseok Lee
Gyeongseok Lee
JPJeongeun Park
Jeongeun Park
HJHyein Jung
Hyein Jung
HLHyukjin Lee
Hyukjin Lee
During the COVID-19 pandemic, mRNA vaccines emerged as a rapid and effective solution for global immunization. The success of COVID-19 mRNA vaccines has increased interest in the use of lipid nanoparticles (LNPs) for the in vivo delivery of mRNA therapeutics. Although mRNA exhibits robust expression profiles, transient protein expression is often observed, raising uncertainty regarding the frequency of its administration. Additionally, various RNA therapeutics may necessitate repeated dosing to achieve optimal therapeutic outcomes. Nevertheless, the impact of repeated administrations of mRNA/LNP on immune responses and protein expression efficacy remains unclear. In this study, we investigated the influence of the formulation parameters, specifically ionizable lipids and polyethylene glycol (PEG) lipids, on the repeat administration of mRNA/LNP. Our findings revealed that ionizable lipids had no discernible impact on the dose-responsive efficacy of repeat administrations, whereas the lipid structure and molar ratio of PEG lipids were primary factors that affected mRNA/LNP performance. The optimization of the LNP formulation with PEG lipid confirmed the sustained dose-responsive efficacy of mRNA after repeated administrations. This study highlights the critical importance of optimizing LNP formulations for mRNA therapeutics requiring repeated administrations.